The use of the biosimilar drug can lead to large health care savings that can be reinvested for continued innovation: Analysis of consumption of an Italian health care company-Reference-Cited by-同舟云学术

The use of the biosimilar drug can lead to large health care savings that can be reinvested for continued innovation: Analysis of consumption of an Italian health care company

Published:2024-06 Issue: Volume:40 Page:100473
ISSN:2213-5383
Container-title:Journal of Cancer Policy
language:en
Short-container-title:Journal of Cancer Policy

Author:

Ferrara Francesco,Capuozzo Maurizio^ORCID,Langella Roberto,Trama Ugo,Nava Eduardo,Zovi Andrea

Publisher

Elsevier BV

Reference23 articles.

1. Immunogenicity to biological drugs in psoriasis and psoriatic arthritis;Valenzuela;Clinics,2021

2. Assessment of expenditure control and prescriptive appropriateness of biological drugs in autoimmune diseases and chronic inflammatory bowel disease;Capuozzo;Front. Pharmacol.,2013

3. Biosimilar medicines - review;Dos Reis;Int. J. Risk Saf. Med.,2016

4. Epidemiology and economic impact of celiac disease in the South vesuvian area of naples: a survey;Capuozzo;Front. Public Health,2013

5. Funds reimbursement of high-cost drugs in gastrointestinal oncology: an Italian real practice 1 year experience at the national cancer institute of Naples;Capozzi;Front. Public Health,2018

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Corrigendum to “The use of the biosimilar drug can lead to large health care savings that can be reinvested for continued innovation: Analysis of consumption of an Italian health care company” [J. Cancer Pol. 40 (2024) 100473];Journal of Cancer Policy;2024-09

2. Corrigendum to “The use of the biosimilar drug can lead to large health care savings that can be reinvested for continued innovation: Analysis of consumption of an Italian health care company” J. Cancer Policy. 40 (2024) 100473;Journal of Cancer Policy;2024-09